New radioactive drug takes aim at Hard-to-Treat prostate cancer
NCT ID NCT06229366
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called [Ac-225]-PSMA-62 in people with prostate cancer that has spread to other parts of the body. The drug delivers a small amount of radiation directly to cancer cells. The main goals are to find the safest dose and to see if it can shrink tumors or slow the disease. About 142 adults with either hormone-sensitive or castration-resistant prostate cancer will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BC Cancer Vancouver
Vancouver, V5Z4E6, Canada
-
Centre Hospitalier Universite de QUEBEC
Québec, G1J 1Z4, Canada
-
Hopital De Chicoutimi
Saguenay, G7H 5H6, Canada
-
Jewish General Hospital
Montreal, H3T 1E2, Canada
-
Juravinski
Hamilton, L8V 5C2, Canada
-
McGill University
Montreal, H4A 3J1, Canada
-
Princess Margaret Cancer Centre
Toronto, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can a new pill outsmart resistant prostate cancer?
- A second look: MRI screening may spot hidden prostate cancers
- Can a radioactive 'Smart Bomb' outsmart advanced prostate cancer?